These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30681344)

  • 21. The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil.
    Ertürk AS; Gürbüz MU; Tülü M
    Pharm Dev Technol; 2017 Feb; 22(1):111-121. PubMed ID: 27484586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
    Naka T; Kubo K
    Curr Pharm Des; 1999 Jun; 5(6):453-72. PubMed ID: 10390609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure.
    Ferreirós N; Dresen S; Alonso RM; Weinmann W
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Aug; 855(2):134-8. PubMed ID: 17478126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
    Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.
    Raasch W; Jöhren O; Schwartz S; Gieselberg A; Dominiak P
    J Hypertens; 2004 Mar; 22(3):611-8. PubMed ID: 15076168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel O-[(11)C]methylated derivatives of candesartan as angiotensin II AT(1) receptor imaging ligands: radiosynthesis and ex vivo evaluation in rats.
    Hadizad T; Kirkpatrick SA; Mason S; Burns K; Beanlands RS; Dasilva JN
    Bioorg Med Chem; 2009 Dec; 17(23):7971-7. PubMed ID: 19879152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers.
    Debernardi-Venon W; Martini S; Biasi F; Vizio B; Termine A; Poli G; Brunello F; Alessandria C; Bonardi R; Saracco G; Rizzetto M; Marzano A
    J Hepatol; 2007 Jun; 46(6):1026-33. PubMed ID: 17336417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacological profiles of candesartan cilexetil (TCV-116)].
    Inada Y
    Nihon Rinsho; 1999 May; 57(5):1130-6. PubMed ID: 10361446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
    Riegger GA; Bouzo H; Petr P; Münz J; Spacek R; Pethig H; von Behren V; George M; Arens H
    Circulation; 1999 Nov; 100(22):2224-30. PubMed ID: 10577995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K; Naka T; Chatani F; Yoshimura Y
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S; Reddy VA; Arora S; Patel K
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Candesartan cilexetil on regular hemodialysis: inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients.
    Rostoker G; Griuncelli M; Benmaadi A
    Ren Fail; 2006; 28(4):283-6. PubMed ID: 16771242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation, characterization and
    Amer AM; Allam AN; Abdallah OY
    Drug Dev Ind Pharm; 2019 Jul; 45(7):1140-1148. PubMed ID: 30912678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.